Evans RN, Reeves BC, Maguire MG, et al. - This study was undertaken to determine if visual and anatomic outcomes in eyes with neovascular age-related macular degeneration (nAMD) initiating anti-vascular endothelial growth factor (VEGF) treatment are correlated with fluctuations in retinal thickness. Data were obtained from February 2008 to November 2012, and data were examined from April 2017 to April 2020. Increasing variation in retinal thickness was related to worse outcomes in post hoc analyses of protocol-directed treatment regimens in this study of 1,731 candidates [mean (SD) age was 78.6 (7.4) years] from 2 randomized clinical trials. Such results indicate that fluctuating activity in eyes with nAMD treated with anti–VEGF drugs can be a marker for poor prognosis. When advising patients about their prognosis, practitioners may need to consider variance in retinal thickness.